CA-SCIENTIST.COM
9.4.2024 13:56:31 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that Sanguine Biosciences, a leading biospecimen provider that connects researchers to the biospecimens they need with a direct-to-donor model to accelerate precision medicine and cell and gene therapy research and development, has successfully completed a VERIF.i® on-site assessment. VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.
“Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman. “Scientist.com’s VERIF.i program enables us to further demonstrate the exceptional quality of our biospecimen and biorepository services and the commitment of our team to bridge the gap between donors and researchers.”
Sanguine supports translational, clinical, and cell and gene therapy research, and their services include prospective in-home biospecimen collection directly from their donor network, apheresis products including leukopaks and LeukoLots™, biospecimen inventory, and biorepository services. Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.
“Human biological samples increasingly represent critical tools in the drug discovery and development process, but researchers in the life sciences often have difficulty finding high-quality, ethically sourced human samples,” stated Matt McLoughlin, SVP of Categories & Compliance at Scientist.com. “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”
For more information on VERIF.i, visit https://www.scientist.com/verifi/
About Sanguine Biosciences
Sanguine Biosciences is accelerating the adoption of personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. By merging annotated patient biospecimens with real-world and analytical data, Sanguine delivers actionable biomarker discovery and validation studies that bridge the gap between patients and scientists working on innovative therapies. In supporting translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies, Sanguine has accelerated R&D and increased confidence in drug development and manufacturing pipelines. For the past four years, Sanguine has received the prestigious designation as a "Great Places to Work'' company. In 2023, Sanguine was designated on the Inc. 5000 America's Fastest Growing Private Companies list, Fortune Best Workplaces in BioPharma, and Fortune Best Small Workplaces. Visit sanguinebio.com to learn more.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409671820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply S.p.A: The Board of Directors Approves theHalf-year Financial Reportas of 30 June 202630.7.2026 13:52:00 CEST | Press release
All economic and financial indicators grew:Consolidated turnover of €1,311.9 million (1,221.3 in H1 2025);EBITDA of €233.2 million (223.7 in H1 2025);EBIT a of €189.7 million (188.4 in H1 2025);Pre-tax profit of €194.1 million (179.4 in H1 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 30 June 2026. Since the start of the year, the Group has recorded a consolidated turnover of €1,311.9 million which is an increase of 7.4% compared to the same period in 2025. All indicators are positive for the period. In the first half of 2026 consolidated EBITDA of €233.2 million compared to the €223.7 million recorded in 2025 and corresponds to 17.8% of turnover. EBIT, from January to June, was €189.7 million (€188.4 million in 2025), corresponding to 14.5% of turnover. Pre-tax profit, from January to June 2026, was €194.1 million (€179.4 million in 2025), corresponding to 14.8% of turnover. As regards the second quarter of 2026, the Group's performan
De' Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision30.7.2026 13:47:00 CEST | Press release
Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the first half of 2026: In the first half the Group achieved: revenues for € 1,676.3 million, up by 5.8% with respect to last year (+8.0% at constant currency); an adjusted2 Ebitda of € 283.7 million, equal to 16.9% on revenues (vs. 15.2% in H1-25); a net income pertaining to the Group equal to € 141.4 million (+21.2% with respect to last year); a positive net financial position equal to € 686.6 million. CEO Fabio de' Longhi commented: “The solid results for the first half of 2026 provide the ideal backdrop to celebrate our first twenty-five years as a listed company. This milestone marks a transformative journey in which, thanks to the commitment and passion of our people, we have consistently
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease30.7.2026 13:01:00 CEST | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for Early Clinical Development, providing practical guidance on the scientific, clinical, and operational factors shaping the development of emerging B-cell depletion therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730139661/en/ B-cell depletion has become an important area of research in autoimmune disease as developers investigate whether deeper and more sustained depletion may support longer periods of remission and potentially influence immune system recovery. Emerging approaches, including in vivo CAR-T therapies and T-cell engagers, are expanding the range of development strategies available beyond established B-cell-targeting treatments. The white paper looks at the early development decisions sponsors face as t
Industrial Info Resources Launches IIR Envoy™ MCP, Bringing Human-Verified Industrial Intelligence Directly Into AI Through Model Context Protocol30.7.2026 13:00:00 CEST | Press release
Model Context Protocol (MCP) connectivity brings 40 years of human-verified energy and industrial intelligence directly into the AI tools professionals already use. Industrial Info Resources (IIR), a leading provider of energy and industrial market intelligence built on primary research and human verification, today announced the launch of IIR Envoy MCP; this new Model Context Protocol connection plugs IIR's authoritative industrial database directly into the AI platforms professionals already use. As an example, with IIR Envoy MCP, an analyst can ask, "What refinery capacity is offline in Europe since this morning's weather event?" or "Which power plants near Houston have upcoming outages?" and receive an instant, source-cited answer drawn from IIR's live data. As AI becomes increasingly embedded in decision-making tools, the quality of AI-generated insights depends entirely on the quality of the underlying data. IIR Envoy MCP was built on that principle. "The information age was abou
120 Million AI Pay Transactions in a Single Week: AI Shopping Agents Move From Theory to Checkout30.7.2026 12:45:00 CEST | Press release
Agentic commerce is beginning to move from forecast to real-world use in some markets. In China, AI agents are already completing purchases at meaningful scale, and analysts now put the global opportunity at $3–5 trillion by 2030. The debate is shifting as early examples show AI shopping agents completing transactions in some markets. According to NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, its global report The Commerce Revolution: Where East Meets West points to agentic commerce moving from experiment toward everyday infrastructure. According to Ant Group, Alipay AI Pay processed more than 120 million transactions during the week of February 5–11, 2026, while Adobe Analytics reported that traffic from generative AI sources to US retail websites increased by 1,200% between July 2024 and February 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730837106/en/ Agentic commerce is beginning to move fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom